Prof Richard MORIGGL
Director, Ludwig Boltzmann Institute for Cancer Research, Medical University Vienna, Vienna University of Veterinary Medicine, Vienna, Austria.
The talk will describe how oligomeric STAT5 transcription factors drive hematopoietic cancers, where we recently described a new metabolic O-GlcNAc sensor on STAT5 essential for cytokine- driven transformation. We generated hyperactive STAT5 and JAK2 mouse models with graded activity levels of STAT5 to explore their mode of hematopoietic cancer development and progression. These models serve for pre-clinical drug development questions for targeted JAK-STAT inhibition, where we also performed comparative pathology studies. Our unpublished transgenic STAT5 mouse models display insights into post-translational modifications of STAT5A and STAT5B guiding oligomerization and gene transcription with graded pYSTAT5A or pYSTAT5B activityand consequences of chromatin landscape remodeling. We work on mechanistic insights into gene regulation control through the JAK-STAT pathway for cancer development also in solid tumors. Inhibitor work will translate findings from basic research towards clinical application. We follow different strategies to inhibit hyperactive STAT5 activation in patient derived cells or transgenic mouse mo- dels that serve for test systems in preclinical evaluation.
University of Luxembourg – Campus Belval – room MSA 3.370
12.30-14.00 Light lunch provided
University of Luxembourg – Campus Belval – room MSA 3.380
Registration by mail to email@example.com